European multicentre study initiated for 5 years’ follow-up of Episealer® Talus patients
Episurf Medical (Nasdaq: EPIS B) today announces the initiation of a prospective investigator-initiated European multicentre study with 5 years’ follow-up of 25 Episealer® Talus patients. The study is initiated by Prof. Niek van Dijk from FIFA Medical Center of Excellence, Madrid, Spain and surgeries will be performed in a number of European countries. The patients in the study will be followed up over 5 years with the subjective outcome measures VAS pain score, Foot and Ankle Outcome Score (FAOS) and EQ-5D-5L which is an instrument used for evaluation of life quality. Interim results from